Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
|Articles|September 16, 2008
- July31 2003
- Volume 10
- Issue 14
That's Entertainment
Advertisement
Forbes
Ever think you chose the wrong profession? With today's medical profession in some turmoil, more than a few physicians might. Although the average US doctor earns a good salary (about $187,000 per year), others who don't save lives every day are doing a lot better. Here are some numbers courtesy of the 2003 "World's Highest Paid Entertainers & Athletes":
Articles in this issue
about 18 years ago
"The Horses Are at the Starting Gate"about 18 years ago
IRS EYES LEASINGabout 18 years ago
CAR INSURANCE SHOPPINGabout 18 years ago
DOCTORS ONLINEabout 18 years ago
CREDIT CARD HOMEabout 18 years ago
RETIRE IN A HEALTHY STATEabout 18 years ago
TRUSTS & MOREabout 18 years ago
DID YOU KNOW?about 18 years ago
PRN: Harness Human Nature's Quirksabout 18 years ago
WHAT PRIVILEGE?Advertisement
Related to this article
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
3
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
4
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
5